denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Biological therapies, Lymphoid Leukemias, Bispecific Antibody Therapy, Lymphomas, CLL, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, Checkpoint Inhibitor, Diseases, Therapies, Lymphoid Malignancies
Description:
The therapy of CLL has undergone a revolution in the last decade with the availability of highly effective targeted therapies. The options continue to expand with next generation inhibitors and combination therapy. The variety of available options can be confusing and their optimal use over a patient’s entire disease course is still often unclear. More and more patients are developing disease progression after both BTK inhibitors and venetoclax and represent a new significant unmet need. Additionally, Richter’s syndrome, the transformation of CLL to an aggressive lymphoma, remains a major clinical challenge with poor outcomes and is also a significant unmet need.
Dr. Jennifer Brown will discuss the selection of initial therapy in CLL, including BTK inhibitors with or without anti-CD20 antibody and venetoclax-obinutuzumab, as well as recent data on combination therapy, with a focus on BTK inhibitor-venetoclax based combinations. She will discuss the key unanswered questions and challenges in frontline therapy.
Dr. Lydia Scarfo will focus on the growing population of patients with CLL who have been treated with both BTK inhibitors and venetoclax, a population which represents a major unmet clinical need. Her discussion will include the role of non-covalent BTK inhibitors, and cellular therapy (mainly CAR T cell approaches), as well as novel promising investigational agents and strategies.
Dr. Tanya Siddiqi will discuss Richter’s syndrome, the transformation of CLL to an aggressive lymphoma, an event which occurs typically in patients with high risk features. There remains no known effective standard of care and hence clinical trial enrollment is preferred when possible. Novel treatment approaches using combinations of small molecule targeted agents, antibody-based therapy, and/or CAR-T cell therapy appear to be more beneficial than chemoimmunotherapy alone.
Dr. Jennifer Brown will discuss the selection of initial therapy in CLL, including BTK inhibitors with or without anti-CD20 antibody and venetoclax-obinutuzumab, as well as recent data on combination therapy, with a focus on BTK inhibitor-venetoclax based combinations. She will discuss the key unanswered questions and challenges in frontline therapy.
Dr. Lydia Scarfo will focus on the growing population of patients with CLL who have been treated with both BTK inhibitors and venetoclax, a population which represents a major unmet clinical need. Her discussion will include the role of non-covalent BTK inhibitors, and cellular therapy (mainly CAR T cell approaches), as well as novel promising investigational agents and strategies.
Dr. Tanya Siddiqi will discuss Richter’s syndrome, the transformation of CLL to an aggressive lymphoma, an event which occurs typically in patients with high risk features. There remains no known effective standard of care and hence clinical trial enrollment is preferred when possible. Novel treatment approaches using combinations of small molecule targeted agents, antibody-based therapy, and/or CAR-T cell therapy appear to be more beneficial than chemoimmunotherapy alone.